{"id":6569,"date":"2021-03-12T15:45:00","date_gmt":"2021-03-12T15:45:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=6569"},"modified":"2024-05-02T10:07:32","modified_gmt":"2024-05-02T08:07:32","slug":"granulocyte-and-monocyte-apheresis-therapy-for-patientswith-active-ulcerative-colitis-associated-with-covid-19","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/de\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patientswith-active-ulcerative-colitis-associated-with-covid-19\/","title":{"rendered":"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19"},"content":{"rendered":"
\n

Koroku, Miki & Omori, Teppei & Kambayashi, Harutaka & Murasugi, Shun & Kuriyama, Tomoko & Ikarashi, Yuichi & Yonezawa, Maria & Arimura, Ken & Karasawa, Kazunori & Hanafusa, Norio & Kawana, Masatoshi & Tokushige, Katsutoshi.<\/p>\n<\/div>\n\n

\n

Intestinal Research. 2021 DOI:10.5217\/ir.2020.00148.<\/p>\n<\/div>\n\n

\n

Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.<\/p>\n<\/div>\n\n

\n

<\/p>\n<\/div>\n\n

\n

https:\/\/www.irjournal.org\/journal\/view.php?doi=10.5217\/ir.2020.00148<\/a><\/p>\n<\/div>\n\n

\n

https:\/\/www.irjournal.org\/upload\/pdf\/ir-2020-00148.pdf<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Koroku, Miki & Omori, Teppei & Kambayashi, Harutaka & Murasugi, Shun & Kuriyama, Tomoko & Ikarashi, Yuichi & Yonezawa, Maria & Arimura, Ken & Karasawa, Kazunori & Hanafusa, Norio & Kawana, Masatoshi & Tokushige, Katsutoshi. Intestinal Research. 2021 DOI:10.5217\/ir.2020.00148. Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is […]<\/p>\n","protected":false},"template":"","scientific_tags":[325,424,306],"class_list":["post-6569","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-covid-19","scientific_tags-gma","scientific_tags-ulcerative-colitis"],"acf":{"sc_authors":"https:\/\/www.irjournal.org\/journal\/view.php?doi=10.5217\/ir.2020.00148<\/a>\r\n\r\nhttps:\/\/www.irjournal.org\/upload\/pdf\/ir-2020-00148.pdf<\/a>"},"yoast_head":"\nGranulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19 - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patientswith-active-ulcerative-colitis-associated-with-covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19 - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Koroku, Miki & Omori, Teppei & Kambayashi, Harutaka & Murasugi, Shun & Kuriyama, Tomoko & Ikarashi, Yuichi & Yonezawa, Maria & Arimura, Ken & Karasawa, Kazunori & Hanafusa, Norio & Kawana, Masatoshi & Tokushige, Katsutoshi. Intestinal Research. 2021 DOI:10.5217\/ir.2020.00148. Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patientswith-active-ulcerative-colitis-associated-with-covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-02T08:07:32+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patientswith-active-ulcerative-colitis-associated-with-covid-19\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patientswith-active-ulcerative-colitis-associated-with-covid-19\/\",\"name\":\"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19 - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2021-03-12T15:45:00+00:00\",\"dateModified\":\"2024-05-02T08:07:32+00:00\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patientswith-active-ulcerative-colitis-associated-with-covid-19\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19 - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patientswith-active-ulcerative-colitis-associated-with-covid-19\/","og_locale":"de_DE","og_type":"article","og_title":"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19 - Adacyte","og_description":"Koroku, Miki & Omori, Teppei & Kambayashi, Harutaka & Murasugi, Shun & Kuriyama, Tomoko & Ikarashi, Yuichi & Yonezawa, Maria & Arimura, Ken & Karasawa, Kazunori & Hanafusa, Norio & Kawana, Masatoshi & Tokushige, Katsutoshi. Intestinal Research. 2021 DOI:10.5217\/ir.2020.00148. Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patientswith-active-ulcerative-colitis-associated-with-covid-19\/","og_site_name":"Adacyte","article_modified_time":"2024-05-02T08:07:32+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patientswith-active-ulcerative-colitis-associated-with-covid-19\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patientswith-active-ulcerative-colitis-associated-with-covid-19\/","name":"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19 - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2021-03-12T15:45:00+00:00","dateModified":"2024-05-02T08:07:32+00:00","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patientswith-active-ulcerative-colitis-associated-with-covid-19\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner\/6569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/media?parent=6569"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific_tags?post=6569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}